KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Current Leases: 2020-2024

Historic Current Leases for Recursion Pharmaceuticals (RXRX) over the last 4 years, with Dec 2024 value amounting to $13.8 million.

  • Recursion Pharmaceuticals' Current Leases rose 39.99% to $11.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.5 million, marking a year-over-year increase of 39.99%. This contributed to the annual value of $13.8 million for FY2024, which is 125.56% up from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Current Leases of $13.8 million as of FY2024, which was up 125.56% from $6.1 million recorded in FY2023.
  • In the past 5 years, Recursion Pharmaceuticals' Current Leases registered a high of $13.8 million during FY2024, and its lowest value of $467,000 during FY2020.
  • In the last 3 years, Recursion Pharmaceuticals' Current Leases had a median value of $6.1 million in 2023 and averaged $8.6 million.
  • Data for Recursion Pharmaceuticals' Current Leases shows a peak YoY spiked of 125.56% (in 2024) over the last 5 years.
  • Over the past 4 years, Recursion Pharmaceuticals' Current Leases (Yearly) stood at $467,000 in 2020, then reached $6.0 million in 2022, then grew by 2.76% to $6.1 million in 2023, then surged by 125.56% to $13.8 million in 2024.